Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Stuart Mair"'
Autor:
Rajula Gaur, Kofi A. Mensah, Jason Stricker, Mary Adams, Anastasia Parton, Dorota Cedzik, Jamie Connarn, Michael Thomas, Gerald Horan, Peter Schafer, Stuart Mair, Maria Palmisano, Francisco Ramírez-Valle
Publikováno v:
Arthritis Research & Therapy, Vol 24, Iss 1, Pp 1-15 (2022)
Abstract Background Mitogen-activated protein kinase (MAPK)-activated protein kinase-2 (MK2) is activated downstream of p38 MAPK and regulates stability of mRNAs encoding inflammatory cytokines. CC-99677 is a novel, irreversible, covalent MK2 inhibit
Externí odkaz:
https://doaj.org/article/bbdb650c3cdc4da7b9496d707ec64951
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 10, Iss 5, Pp 1027-1035 (2019)
Abstract Background Loss of appetite and body weight are potentially devastating, highly prevalent cancer complications. The ghrelin receptor is a mediator of appetite and metabolism, and anamorelin is a novel, orally administered ghrelin receptor ag
Externí odkaz:
https://doaj.org/article/70004e060f154e1b9505c65de686beb9
Autor:
Shahzadgai Khan, Muna Albayaty, James Bush, Joseph Cheriyan, Anthea Cromie, Annelize Koch, Michael Hammond, Stuart Mair, Ulrike Lorch, Steffan Stringer, Jorg Taubel, Timothy C. Hardman
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
The Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI) annual meeting focused on impending change, innovation, and future challenges facing early phase drug development as we move into the second decade of the 21th century. The
Externí odkaz:
https://doaj.org/article/126a543321ad49788d3af82a37356081
Autor:
Susan Reijntjes, Muna Albayaty, James Bush, Joseph Cheriyan, Anthea Cromie, Annelize Koch, Michael Hammond, Stuart Mair, Peter Scholes, Ulrike Lorch, Steffan Stringer, Jorg Taubel, Timothy C. Hardman
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
The Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI) annual meeting focused on the changing face of early phase drug development and opened with a keynote speech concerning the revolution in pharmaceutical medicine over the l
Externí odkaz:
https://doaj.org/article/142ed6f8be4d431691147e0fb3990447
Autor:
Rajula Gaur, Kofi A. Mensah, Jason Stricker, Mary Adams, Anastasia Parton, Dorota Cedzik, Jamie Connarn, Michael Thomas, Gerald Horan, Peter Schafer, Stuart Mair, Maria Palmisano, Francisco Ramírez-Valle
Publikováno v:
Arthritis researchtherapy. 24(1)
Background Mitogen-activated protein kinase (MAPK)-activated protein kinase-2 (MK2) is activated downstream of p38 MAPK and regulates stability of mRNAs encoding inflammatory cytokines. CC-99677 is a novel, irreversible, covalent MK2 inhibitor under
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 10, Iss 5, Pp 1027-1035 (2019)
Journal of Cachexia, Sarcopenia and Muscle
Journal of Cachexia, Sarcopenia and Muscle
Background Loss of appetite and body weight are potentially devastating, highly prevalent cancer complications. The ghrelin receptor is a mediator of appetite and metabolism, and anamorelin is a novel, orally administered ghrelin receptor agonist. Ef
Autor:
Annelize Koch, Ulrike Lorch, Muna Albayaty, Joseph Cheriyan, Steffan Stringer, Shahzadgai Khan, Anthea Cromie, Michael Hammond, Jorg Taubel, Stuart Mair, Timothy C. Hardman, James Bush
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 11 (2020)
Frontiers in Pharmacology, Vol 11 (2020)
The Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI) annual meeting focused on impending change, innovation and future challenges facing early phase drug development as we move into the second decade of the twenty first centu
Autor:
Diane Gesty-Palmer, Yarlagadda S. Babu, Cynthia Parker, David Reynolds, Xilin Chen, Matthew G. Davidson, Melanie Cornpropst, William P. Sheridan, Stuart Mair, Amanda Mathis
Publikováno v:
Blood. 136:15-16
INTRODUCTION: Complement factor D is the rate-limiting enzyme for activation of the complement alternative pathway (AP). Targeting factor D is therefore an attractive therapeutic strategy for treatment of AP-mediated diseases including paroxysmal noc
Autor:
Walter J. Doll, Joyce James, Erik P. Sandefer, M. Scott Harris, Stuart Mair, David Wurtman, Adam M. Deane, Alan H. Maurer
Publikováno v:
Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility SocietyREFERENCES. 32(3)
BACKGROUND: Ulimorelin, a small molecule ghrelin agonist and prokinetic agent, was effective in animal models of gastroparesis and delayed transit. However, employing once daily administration, it failed in clinical trials of postoperative ileus (POI
Autor:
Megumi Furukawa, Shinsuke Inoue, Stuart Mair, Takahiro Goto, Atsuhiro Kawaguchi, Takayuki Kifuji, Hiroshi Kumagai, Begonya Perez Madera
The absorption, metabolism and excretion of MT-1303 were investigated in healthy male subjects after a single oral dose of 0.4 mg [14C]-MT-1303 (ClinicalTrials.gov NCT02293967).The MT-1303 concentration in the plasma reached a maximum at 12 h after a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bca2e5a22160e4aec937dc4fc54ddf8